adamantane has been researched along with Nausea in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderton, K; Bentz, TA; Brisendine, A; Britten, CD; Chin, SH; Cusack, SL; Garrett-Mayer, E; Maines, LW; Ogretmen, B; Shirai, K; Smith, CD; Thomas, MB; Zhuang, Y | 1 |
| Brown, C; Fan, P; Makriyannis, A; McLaughlin, PJ; Olszewska, T; Olzewska, T; Pang, Y; Parker, LA; Peng, Y; Salamone, JD; Sink, KS; Thakur, GA; Vemuri, VK; Wood, JA | 1 |
| Campestrini, J; Deacon, CF; He, YL; Holst, JJ; Ligueros-Saylan, M; Nielsen, JC; Riviere, GJ; Schwartz, S; Serra, D; Wang, Y | 1 |
| Campestrini, J; Dole, K; Dole, WP; He, YL; Howard, D; Ligueros-Saylan, M; Marion, A; Pommier, F; Sabo, R; Sunkara, G; Wang, Y; Zhao, C | 1 |
| Mikhail, N | 1 |
1 review(s) available for adamantane and Nausea
| Article | Year |
|---|---|
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Topics: Adamantane; Body Weight; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Nausea; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Vomiting | 2008 |
3 trial(s) available for adamantane and Nausea
| Article | Year |
|---|---|
A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors.
Topics: Adamantane; Adult; Aged; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Pyridines; Treatment Outcome; Vomiting; Young Adult | 2017 |
Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.
Topics: Adamantane; Administration, Oral; Adult; Aged; Area Under Curve; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Half-Life; Humans; Hypoglycemic Agents; Male; Middle Aged; Nausea; Nitriles; Pyrrolidines; Treatment Outcome; Vildagliptin; Vomiting | 2007 |
Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
Topics: Adamantane; Administration, Oral; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Area Under Curve; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Half-Life; Headache; Humans; Male; Middle Aged; Nausea; Nitriles; Pyrrolidines; Ramipril; Tablets; Tetrazoles; Valine; Valsartan; Vildagliptin | 2008 |
1 other study(ies) available for adamantane and Nausea
| Article | Year |
|---|---|
The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats.
Topics: Adamantane; Analysis of Variance; Animals; Behavior, Animal; Conditioning, Operant; Cyclic AMP; Dose-Response Relationship, Drug; Dronabinol; Drug Interactions; Eating; Male; Motor Activity; Nausea; Piperidines; Protein Binding; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Reinforcement, Psychology | 2008 |